Shanghai Pharmaceuticals Holding Co Ltd (Shanghai Pharma) discovers, manufactures, and markets pharmaceutical products to treat various chronic diseases. The company manufactures its products under renowned brands, including SINE, Dragon & Tiger, Growful, Dinglu, Cangsong, Huqingyutang, and Qingchunbao.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Shanghai Pharma has undertaken several research and development (R&D) initiatives, including the establishment of the Industrial Innovation Council of the Scientific Committee to guide development strategy, R&D layout, and product planning. The company has also achieved major breakthroughs in its innovative drug pipeline, with the approval of the class I innovative drug Stogilan Malate Tablet for primary hypertension. The company has promoted the adjustment of its R&D management organizational structure to enhance professional division of labor and reduce redundancy. It has also deepened cooperation with universities and research institutes, focusing on biomedicine and promoting high-level basic research and achievements transformation. The company is actively involved in cell and gene therapy, establishing Shanghai Kangjiansheng Cell Technology Co., Ltd. and signing strategic cooperation agreements to advance cell therapy research and industrialization. Additionally, the company has introduced an open-source innovation system and collaborated with various institutions to foster innovation and industrialization of technological achievements. The R&D units of Shanghai Pharma include the Shanghai Pharmaceuticals Central Research Institute and the newly established Industrial Innovation Council of the Scientific Committee. These units are responsible for guiding development strategy, R&D layout, product planning, and promoting the professional division of labor. They also focus on resource sharing, talent employment, and collaboration with universities and research institutes to drive innovation and industrialization. In FY2025, the company spent CNY2,340 million on its R&D activities, which, as a percentage of revenue, stood at 0.8%. As of December 2025, the company had 59 new drug pipelines for clinical application acceptance and entering the clinical study stage, including 47 innovative drugs and 12 improved new drugs. Among these, one innovative drug pipeline has been applied for marketing, and six are in clinical Phase III. The company has also established major technology alliances with institutions such as Shanghai Jiao Tong University, Fudan University, and the Chinese Academy of Sciences. Some of its pipeline drugs in Phase III clinical trials include SRD4610 to treat Amyotrophic lateral sclerosis; BCD-100 to treat Non-small cell lung cancer; BCD-085 to treat Psoriasis and Ankylosing spondylitis; and B001-C to treat Neuromyelitis optica.